Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
received:
15
11
2023
accepted:
17
05
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
5
6
2024
Statut:
epublish
Résumé
Cancer patients often undergo rounds of trial-and-error to find the most effective treatment because there is no test in the clinical practice for predicting therapy response. Here, we conduct a clinical study to validate the zebrafish patient-derived xenograft model (zAvatar) as a fast predictive platform for personalized treatment in colorectal cancer. zAvatars are generated with patient tumor cells, treated exactly with the same therapy as their corresponding patient and analyzed at single-cell resolution. By individually comparing the clinical responses of 55 patients with their zAvatar-test, we develop a decision tree model integrating tumor stage, zAvatar-apoptosis, and zAvatar-metastatic potential. This model accurately forecasts patient progression with 91% accuracy. Importantly, patients with a sensitive zAvatar-test exhibit longer progression-free survival compared to those with a resistant test. We propose the zAvatar-test as a rapid approach to guide clinical decisions, optimizing treatment options and improving the survival of cancer patients.
Identifiants
pubmed: 38839755
doi: 10.1038/s41467-024-49051-0
pii: 10.1038/s41467-024-49051-0
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4771Subventions
Organisme : Ministry of Education and Science | Fundação para a Ciência e a Tecnologia (Portuguese Science and Technology Foundation)
ID : FCT-PTDC/MEC-ONC/31627/2017
Organisme : Ministry of Education and Science | Fundação para a Ciência e a Tecnologia (Portuguese Science and Technology Foundation)
ID : LISBOA-01-0145-FEDER-022170
Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L. et al. Colorectal cancer statistics, 2020. CA: A Cancer J. Clin. 70, 145–164 (2020).
Baxter, N. N. et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J. Clin. Oncol. 40, 892–910 (2021).
doi: 10.1200/JCO.21.02538
pubmed: 34936379
Aparicio, J. et al. Metastatic colorectal cancer. first line therapy for unresectable disease. J. Clin. Med. https://doi.org/10.3390/jcm9123889 (2020).
Cervantes, A. et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆. Ann. Oncol. 34, 10–32 (2023).
doi: 10.1016/j.annonc.2022.10.003
pubmed: 36307056
Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016).
doi: 10.1093/annonc/mdw235
pubmed: 27380959
Colucci, G. et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J. Clin. Oncol. 23, 4866–4875 (2005).
doi: 10.1200/JCO.2005.07.113
pubmed: 15939922
Ikoma, N., Raghav, K. & Chang, G. An update on randomized clinical trials in metastatic colorectal carcinoma. Surg. Oncol. Clin. N. Am. 26, 667–687 (2017).
doi: 10.1016/j.soc.2017.05.007
pubmed: 28923224
pmcid: 5648005
Tournigand, C. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22, 229–237 (2004).
doi: 10.1200/JCO.2004.05.113
pubmed: 14657227
Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543–548 (2013).
doi: 10.1126/science.1227670
pubmed: 23239622
Letai, A. Functional precision medicine: putting drugs on patient cancer cells and seeing what happens. Cancer Discov. 12, 290–292 (2022).
doi: 10.1158/2159-8290.CD-21-1498
pubmed: 35140175
pmcid: 8852353
Pfohl, U. et al. Precision oncology beyond genomics: the future is here-it is just not evenly distributed. Cells https://doi.org/10.3390/cells10040928 (2021).
Deng, J. et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12, 171–185 (2007).
doi: 10.1016/j.ccr.2007.07.001
pubmed: 17692808
Fior, R. et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc. Natl Acad. Sci. USA 114, E8234–e8243 (2017).
doi: 10.1073/pnas.1618389114
pubmed: 28835536
pmcid: 5625889
Chen, X. et al. Invasiveness and metastasis of retinoblastoma in an orthotopic zebrafish tumor model. Sci. Rep. 5, 10351 (2015).
doi: 10.1038/srep10351
pubmed: 26169357
pmcid: 4501005
Costa, B., Estrada, M. F., Mendes, R. V. & Fior, R. Zebrafish avatars towards personalized medicine—a comparative review between avatar models. Cells https://doi.org/10.3390/cells9020293 (2020).
Durinikova, E., Buzo, K. & Arena, S. Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges. J. Exp. Clin. Cancer Res. 40, 185 (2021).
doi: 10.1186/s13046-021-01981-z
pubmed: 34090508
pmcid: 8178911
Gamble, J. T., Elson, D. J., Greenwood, J. A., Tanguay, R. L. & Kolluri, S. K. The zebrafish xenograft models for investigating cancer and cancer therapeutics. Biology https://doi.org/10.3390/biology10040252 (2021).
Ali, Z. et al. Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer. J. Exp. Clin. Cancer Res. 41, 58 (2022).
doi: 10.1186/s13046-022-02280-x
pubmed: 35139880
pmcid: 8827197
Costa, B. et al. Developments in zebrafish avatars as radiotherapy sensitivity reporters—towards personalized medicine. EBioMedicine 51, 102578 (2020).
doi: 10.1016/j.ebiom.2019.11.039
pubmed: 31862441
Di Franco, G. et al. Zebrafish patient-derived xenograft model to predict treatment outcomes of colorectal cancer patients. Biomedicines 10, 1474 (2022).
doi: 10.3390/biomedicines10071474
pubmed: 35884780
pmcid: 9313122
Gauert, A. et al. Fast, in vivo model for drug-response prediction in patients with B-cell precursor acute lymphoblastic leukemia. Cancers https://doi.org/10.3390/cancers12071883 (2020).
Lin, J. et al. A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. Blood 128, 249–252 (2016).
doi: 10.1182/blood-2016-03-704460
pubmed: 27207793
pmcid: 4946203
Usai, A. et al. Zebrafish patient-derived xenografts identify chemo-response in pancreatic ductal adenocarcinoma patients. Cancers https://doi.org/10.3390/cancers13164131 (2021).
Wu, J. Q. et al. Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer. J. Exp. Clin. Cancer Res. 36, 160 (2017).
doi: 10.1186/s13046-017-0631-0
pubmed: 29141689
pmcid: 5688753
Zhai, J. et al. Prediction of sensitivity and efficacy of clinical chemotherapy using larval zebrafish patient-derived xenografts of gastric cancer. Front. Cell Dev. Biol. 9, 680491 (2021).
doi: 10.3389/fcell.2021.680491
pubmed: 34164399
pmcid: 8215369
Follain, G. et al. Hemodynamic forces tune the arrest, adhesion, and extravasation of circulating tumor cells. Dev. Cell 45, 33–52.e12 (2018).
doi: 10.1016/j.devcel.2018.02.015
pubmed: 29634935
Osmani, N. et al. Metastatic tumor cells exploit their adhesion repertoire to counteract shear forces during intravascular arrest. Cell Rep. 28, 2491–2500.e2495 (2019).
doi: 10.1016/j.celrep.2019.07.102
pubmed: 31484062
Paul, C. D. et al. Tissue architectural cues drive organ targeting of tumor cells in zebrafish. Cell Syst. 9, 187–206.e116 (2019).
doi: 10.1016/j.cels.2019.07.005
pubmed: 31445892
pmcid: 8276582
Wakefield, L., Agarwal, S. & Tanner, K. Preclinical models for drug discovery for metastatic disease. Cell 186, 1792–1813 (2023).
doi: 10.1016/j.cell.2023.02.026
pubmed: 37059072
de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374–403 (2023).
doi: 10.1016/j.ccell.2023.02.016
pubmed: 36917948
Pavlič, A., Urh, K., Štajer, K., Boštjančič, E. & Zidar, N. Epithelial-mesenchymal transition in colorectal carcinoma: comparison between primary tumor, lymph node and liver metastases. Front. Oncol. https://doi.org/10.3389/fonc.2021.662806 (2021).
Brown, K. M. et al. Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity. J. Surg. Res. 227, 158–167 (2018).
doi: 10.1016/j.jss.2018.02.018
pubmed: 29804848
Ganesh, K. et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat. Med. 25, 1607–1614 (2019).
doi: 10.1038/s41591-019-0584-2
pubmed: 31591597
pmcid: 7385919
Geevimaan, K. et al. Patient-derived organoid serves as a platform for personalized chemotherapy in advanced colorectal cancer patients. Front. Oncol. 12, 883437 (2022).
doi: 10.3389/fonc.2022.883437
pubmed: 35719949
pmcid: 9205170
Izumchenko, E. et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann. Oncol. 28, 2595–2605 (2017).
doi: 10.1093/annonc/mdx416
pubmed: 28945830
pmcid: 5834154
Ooft, S. N. et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci. Transl. Med. 11, eaay2574 (2019).
doi: 10.1126/scitranslmed.aay2574
pubmed: 31597751
Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920–926 (2018).
doi: 10.1126/science.aao2774
pubmed: 29472484
pmcid: 6112415
Yao, Y. et al. Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 26, 17–26.e16 (2020).
doi: 10.1016/j.stem.2019.10.010
pubmed: 31761724
Miyoshi, H. et al. An improved method for culturing patient-derived colorectal cancer spheroids. Oncotarget 9, 21950–21964 (2018).
doi: 10.18632/oncotarget.25134
pubmed: 29774115
pmcid: 5955161
Pasch, C. A. et al. Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation. Clin. Cancer Res. 25, 5376–5387 (2019).
doi: 10.1158/1078-0432.CCR-18-3590
pubmed: 31175091
pmcid: 6726566
Cashin, P. H. et al. Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases. Br. J. Surg. 110, 1080–1083 (2023).
doi: 10.1093/bjs/znad066
pubmed: 36918737
pmcid: 10416678
da Mata, S. et al. Patient-derived explants of colorectal cancer: histopathological and molecular analysis of long-term cultures. Cancers https://doi.org/10.3390/cancers13184695 (2021).
Martin, S. Z. et al. Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. BMC Cancer 19, 1030 (2019).
doi: 10.1186/s12885-019-6270-4
pubmed: 31675944
pmcid: 6824140
Vera, R. et al. Recommendations for follow-up of colorectal cancer survivors. Clin. Transl. Oncol. 21, 1302–1311 (2019).
doi: 10.1007/s12094-019-02059-1
pubmed: 30762206
Costa, B., Estrada, M. F., Barroso, M. T. & Fior, R. Zebrafish patient-derived avatars from digestive cancers for anti-cancer therapy screening. Curr. Protoc. 2, e415 (2022).
doi: 10.1002/cpz1.415
pubmed: 35436037
Lawson, N. D. & Weinstein, B. M. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev. Biol. 248, 307–318 (2002).
doi: 10.1006/dbio.2002.0711
pubmed: 12167406
Martinez-Lopez, M., Póvoa, V. & Fior, R. Generation of zebrafish larval xenografts and tumor behavior analysis. J. Vis. Exp. https://doi.org/10.3791/62373 (2021).
Rebelo de Almeida, C. et al. Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy. Commun. Biol. 3, 299 (2020).
doi: 10.1038/s42003-020-1015-0
pubmed: 32523131
pmcid: 7286887